Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry

Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients

(2022) Soonwook Kwon et al.   CEPHALALGIA

A real‐world, observational study of erenumab for migraine prevention in Canadian patients

(2022) Werner J. Becker et al.   HEADACHE

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study

(2022) Christopher Kjaer Cullum et al.   JOURNAL OF HEADACHE AND PAIN

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

(2022) Piero Barbanti et al.   JOURNAL OF HEADACHE AND PAIN

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE

(2022) Taoufik Alsaadi et al.   BMC Neurology

Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience

(2022) Claudia Altamura et al.   JOURNAL OF NEUROLOGY

Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine

(2022) Damiana Scuteri et al.   Toxins

Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review

(2022) Ann M. Murray et al.   Current Pain and Headache Reports

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine

(2022) Andreas A. Argyriou et al.   Toxins

Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders

(2021) Andreas A. Argyriou et al.   Expert Review of Neurotherapeutics

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials

(2019) Stephen D. Silberstein et al.   HEADACHE

Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats

(2019) Agustin Melo-Carrillo et al.   CEPHALALGIA

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

(2018) Cristina Tassorelli et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Fremanezumab: First Global Approval

(2018) Sheridan M. Hoy   DRUGS

Blocking CGRP in migraine patients – a review of pros and cons

(2017) Marie Deen et al.   JOURNAL OF HEADACHE AND PAIN

Fremanezumab - a humanized monoclonal anti-CGRP antibody — inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors

(2017) Agustin Melo-Carrillo et al.   JOURNAL OF NEUROSCIENCE

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

(2015) Lars Edvinsson   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development

(2013) Marcelo E. Bigal et al.   HEADACHE

Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations

(2007) Robert H. Dworkin et al.   JOURNAL OF PAIN